Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS

Haematologica. 2020 Oct 1;105(10):e512. doi: 10.3324/haematol.2019.243170.

Authors

Affiliations

¹ Institute of Hematology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
² Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
³ National Cancer Institute, Aviano, Italy.
⁴ Division of Hematology, IRCCS Policlinico San Matteo, Pavia, Italy.
⁵ National Cancer Institute, Fondazione Pascale, IRCCS, Napoli, Italy.
⁶ Institute of Hematology L. e A. Seràgnoli University of Bologna, Bologna, Italy.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Brentuximab Vedotin
Hodgkin Disease* / drug therapy
Humans
Immunoconjugates*
Neoplasm Recurrence, Local / drug therapy
Recurrence

Substances

Immunoconjugates
Brentuximab Vedotin

Grants and funding

Funding. this study was partially supported by Takeda (ID X25008).